Melasma. Chloasma
Conditions
Interventions
Intervention 1: Intervention group: The intervention group receives oral Depigmaglocal© capsule (manufactured by Persian Pad Company) that should be consumed once daily plus topical Tranexamic Acid so
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with melasma Aged 18 to 60 years old
Exclusion criteria
Exclusion criteria: Pregnant women Lactating women Patients with chronic renal failure and end-stage renal disease cirrhosis and end-stage liver disease Patients with autoimmune disorders such as systemic lupus erythematous, allergy to grape, fern species, and carotenoids Unwillingness to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of Melasma and darkness. Timepoint: Before the start of the study and three months after the start of the interventions. Method of measurement: Using modified Melasma Area and Severity Index Scale (m-MASI), DermaCatch, and Visioface. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's quality of life. Timepoint: Before the start of the study and three months after the start of the interventions. Method of measurement: melasma Quality of Life questionnaire (melasQOL). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Arezoo Hosseini
Shiraz University of Medical Sciences
Outcome results
None listed